Cardiol Therapeutics Inc Class A experienced notable price movements this week, reflecting key developments in the company's journey.
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock price fluctuate, closing at C$1.75 after a decline of 2.87% on Monday. However, the stock has shown resilience over the past week, with a gain of 17.36%. Investors are keen to understand the underlying factors influencing these movements, especially amidst recent announcements and clinical developments.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The stock's recent performance highlights the importance of monitoring clinical trial outcomes and investor sentiment in the biotech sector, particularly for companies like Cardiol Therapeutics that are focused on innovative therapies.
C$1.75 closing price reflects a 17.36% increase over the past week.
With a 52-week range of C$1.23 to C$2.33, the stock is currently positioned at 48% of its range, indicating potential for both upside and downside as market conditions evolve.
Bull case
Positive results from clinical trials and publications in respected journals can boost investor confidence and potentially increase the stock's value as the company advances its research.
Bear case
The stock's volatility, along with the company's negative return on equity (ROE) and profit margin, may raise concerns for risk-averse investors, especially in a sector known for its unpredictability.
Price Action Overview
Cardiol Therapeutics Inc Class A (CRDL.TO) closed at C$1.75 on Monday, marking a decrease of 2.87% for the day. Despite this dip, the stock has performed well over the past week, gaining 17.36%. Year-to-date, the stock has appreciated by 24.26%, reflecting a positive sentiment among investors.
Recent Company News
This week, Cardiol Therapeutics garnered attention following the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. This publication highlights the effectiveness of CardiolRx™ in managing recurrent pericarditis, which could attract more investor interest. Additionally, the company participated in fireside chats at investment summits, which may help enhance its visibility within the investment community.
Technical Picture
From a technical standpoint, Cardiol Therapeutics' stock is currently trading above both its 50-day moving average (C$1.62) and 200-day moving average (C$1.54), indicating a bullish trend. The stock has a beta of 0.51, suggesting lower volatility compared to the broader market. The recent trading volume of 136,772 shares is notably higher than the 20-day average volume of 59,240 shares, indicating increased investor activity.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
